Factors predictive of survival after first relapse or progression in advanced epithelial ovarian carcinoma: A prediction tree analysis-derived model with test and validation groups

Gynecologic Oncology

Volumn 70, Issue 2, 1998, Pages 224-230

  Hoskins, P ^a   Tu, D ^b   James, K ^b   Pater, J ^b   Koski, B ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Canada   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MODEL; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; VALIDATION PROCESS;

EID: 0032143553     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5074     Document Type: Article

References (28)

1. Hoskins P J, O'Reilly S E, Swenerton K D, Spinelli J J, Fairey R N, Benedet J L. Ten year outcome of patients with advanced epithelial ovarian carcinoma treated with cisplatin-based multimodality therapy. J Clin Oncol. 10:1992;1561-1568.
2. Sutton G P, Stehamn F B, Einhorn L H, Roth L M, Blessing J A, Ehrlich C E. Ten year follow up of patients receiving cisplatin, doxorubicin and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol. 7:1989;223-229.
3. Neijt J P, ten Bokkel Huinink W W, van der Burg M EL, van Oosterom A T, Willemse P HB, Vermorken J B, van Lindert A CM, Heintz A PM, Aartsen E, van Lent M, Trimbos J B, de Meijer A J. Long term survival in ovarian cancer. Eur J Cancer. 27:1991;1367-1372.
4. Hainsworth J D, Grosh W W, Burnett L S, Jones H W, Wolff S N, Greco F A. Advanced ovarian cancer: long term results of treatment with intensive cisplatin-based chemotherapy of brief duration. Ann Intern Med. 108:1988;165-170.
5. Vermorken J B, Hoekman K. Chemotherapy for gynecologic malignancies. Curr Opin Oncol. 7:1996;457-465.
6. Eisenhauer E A, ten Bokkel Huinink W W, Swenerton K D, Gianni L, Myles J, van der Burg M EL, Kerr I, Vermorken J B, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 12:1994;2654-2666.
7. Hoskins P J, O'Reilly S E, Swenerton K D. The "failure free interval" defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int J Gynecol Cancer. 1:1991;205-208.
8. Markman M, Hoskins W J. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol. 10:1992;513-514.
9. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis J L. Second line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
10. Van Glabbeke M, Vermorken J, Eisenhauer E. Predictors of survival (OS) and time to progression (TTP) following second or third line treatment in advanced ovarian cancer (OVCA): an analysis of 744 patients (pts) treated with paclitaxel, docetaxel or high dose epirubicin. Proc Am Soc Clin Oncol. 16:1997;354a.
11. Makar A P, Kristensen G B, Bormer D P, Trope C G. Is serum CA 125 at the time of relapse a prognostic indicator for future survival prognosis in patients with ovarian cancer. Gynecol Oncol. 49:1993;3-7.
12. Gadduci A, Landoni F, Maggino F, Sartoris E, Zola P, Ferdeghini M, Parma G, Cristofani R. Serum Ca 125 assay at time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study. Int J Gynecol Cancer. 7:1997;78-83.
13. Kramer S, Buhler A, Jager W, Lang N. The CA 125 doubling time as an independent prognostic factor in recurrent ovarian cancer. Eur J Gynecol Oncol. 18:1997;269.
14. Khoo S K, Battistuttu D, Hurst T, Sanderson B, Ward B G, Free K. The prognostic value of clinical, pathologic, and biologic parameters in ovarian cancer. Cancer. 72:1993;531-537.
15. Van Houwelingen J C, ten Bokkel Huinink W W, Van der Burg M EL, van Oosterom A T, Neijt J P. Predictability of the survival of patients with advanced ovarian cancer. J Clin Oncol. 7:1989;769-773.
16. Omura G A, Brady M F, Homesley H D, Yordan E, Major F J, Buschbaum H J, Paru R C. Long term follow up and prognostic factor analysis in advanced ovarian cancer: the Gynecologic Oncology Group experience. J Clin Oncol. 9:1991;1138-1150.
17. Swenerton K D, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O'Connell G, MacLean G, Kirk M E, Canetta R, Koski B, Shelley W, Zee B, Pater J. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group (OV.8). J Clin Oncol. 10:1992;718-726.
18. Pater J, Carmichael J A, Krepart G V, Fraser R C, Roy M, Kirk M E, Levitt M, Brown L B, Wilson K S, Shelley W E, Willan A R. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin. Cancer Treat Rep. 71:1987;277-281.
19. Ciampi A, Negassa A, Lou Z. Tree structured prediction for censored survival data and the Cox model. J Clin Epidemiol. 48:1995;675-689.
20. McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
21. Van den Burg M EL, Van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave A J, Nardi M, Renard J, Pecorelli S. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med. 332:1995;629-634.
22. Vermorken, J, B, Eisenhauer, E, A, Lu, F, Fumoleau, P, Canetta, R, Walling, J, van Glabbeke, M, Prognostic features of importance for phase II studies in platinum-pretreated ovarian cancer (OC) patients, Proceedings of the 6th International Conference on Anticancer Treatment, Paris 1996, 130.
23. Swenerton K, Muss H B, Robinson E G. Salvage chemotherapy for refractory disease in ovarian cancer. Controversies in Management. 1998;Churchill Livingstone, London.
24. Morris M, Gershenson D M, Wharton J T, Copeland L J, Edwards C L, Stringer C A. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol. 34:1989;334-338.
25. Morris M, Gershenson D M, Wharton J T. Secondary cytoreductive surgery in epithelial ovarian cancer: non-responders to first-line therapy. Gynecol Oncol. 33:1989;1-5.
26. Eisenkop S M, Friedman R L, Wang H. Secondary cytoreductive surgery for recurrent ovarian cancer. Cancer. 76:1995;1606-1614.
27. Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert J R, Graeff H. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer. 70:1992;2129-2136.
28. Segna R A, Dottino D R, Mandeli J P, Kensker K, Cohen C J. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol. 11:1993;434-439.